[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA914830B - Novel,protracted insulin analogues - Google Patents

Novel,protracted insulin analogues

Info

Publication number
ZA914830B
ZA914830B ZA914830A ZA914830A ZA914830B ZA 914830 B ZA914830 B ZA 914830B ZA 914830 A ZA914830 A ZA 914830A ZA 914830 A ZA914830 A ZA 914830A ZA 914830 B ZA914830 B ZA 914830B
Authority
ZA
South Africa
Prior art keywords
novel
insulin analogues
protracted insulin
protracted
analogues
Prior art date
Application number
ZA914830A
Inventor
Jan Markussen
Markussen Jan
Liselotte Langkjaer
Langkjaer Liselotte
Kjeld Norris
Norris Kjeld
Leo Boye Snel
Boye Snel Leo
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA914830B publication Critical patent/ZA914830B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA914830A 1990-06-28 1991-06-24 Novel,protracted insulin analogues ZA914830B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK155690A DK155690D0 (en) 1990-06-28 1990-06-28 NEW PEPTIDES

Publications (1)

Publication Number Publication Date
ZA914830B true ZA914830B (en) 1992-03-25

Family

ID=8106031

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914830A ZA914830B (en) 1990-06-28 1991-06-24 Novel,protracted insulin analogues

Country Status (10)

Country Link
EP (1) EP0536245A1 (en)
JP (1) JPH05508406A (en)
AU (1) AU8054391A (en)
DK (1) DK155690D0 (en)
IE (1) IE912247A1 (en)
IL (1) IL98596A0 (en)
NZ (1) NZ238718A (en)
PT (1) PT98124A (en)
WO (1) WO1992000321A1 (en)
ZA (1) ZA914830B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CA2215694A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
CN103215328B (en) 2004-01-21 2016-08-03 诺和诺德医疗保健公司 The joint of transglutaminase mediated peptide
US20090306337A1 (en) 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
ES2601839T3 (en) 2006-09-22 2017-02-16 Novo Nordisk A/S Protease resistant insulin analogs
JP5496082B2 (en) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein
ES2613152T3 (en) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh New insulin derivatives with extremely delayed time / action profile
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
ES2609288T3 (en) 2008-03-18 2017-04-19 Novo Nordisk A/S Acylated insulin analogs, stabilized against proteases
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
DE102008064270A1 (en) * 2008-12-20 2010-07-01 Voith Patent Gmbh Flotation method for removing contaminants from aqueous fibrous material suspension by gas bubbles, involves supplying stream of fibrous material suspension along interference body after supplying stream of gas
EP2451471A1 (en) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Slow-acting insulin preparations
PT2451437T (en) 2009-07-06 2017-01-17 Sanofi Aventis Deutschland Aqueous preparations comprising methionine
US20120241356A1 (en) * 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
MA33467B1 (en) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Primary drugs include insulin-linking facilities
KR101759499B1 (en) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 Long acting insulin composition
LT2498801T (en) 2009-11-13 2018-05-10 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
PL3417871T3 (en) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine
WO2011161083A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP5931857B2 (en) * 2010-06-23 2016-06-08 ノヴォ ノルディスク アー／エス Insulin derivatives containing additional disulfide bonds
MX339614B (en) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2.
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
EP2686003A2 (en) * 2011-03-15 2014-01-22 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (en) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014025132A2 (en) 2012-04-11 2017-07-11 Novo Nordisk As insulin formulations
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
ES2625548T3 (en) 2012-06-04 2017-07-19 DiaMedica Therapeutics Inc. Glycosylation isoforms of human tissue calicrein-1
RU2015129087A (en) 2012-12-19 2017-02-02 Вокхардт Лимитед STABLE WATER COMPOSITION CONTAINING HUMAN INSULIN OR ITS ANALOGU OR DERIVATIVE
AU2013368990B2 (en) 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2014326181A1 (en) 2013-09-30 2016-03-17 Wockhardt Limited Pharmaceutical composition
BR112016007166A2 (en) 2013-10-07 2017-09-12 Novo Nordisk As derived from an insulin analog
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN105960249B (en) 2014-01-09 2021-03-16 赛诺菲 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
BR112016013832A2 (en) 2014-01-09 2017-08-08 Sanofi Sa USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CN110087674B (en) 2016-12-16 2023-01-03 诺和诺德股份有限公司 Pharmaceutical composition containing insulin
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
CN111032685A (en) 2017-08-17 2020-04-17 诺沃挪第克公司 Novel acylated insulin analogs and their uses
CN109646396A (en) * 2018-12-29 2019-04-19 江苏万邦医药科技有限公司 A kind of stable insulin analog injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (en) * 1975-08-13 1977-02-24 Hoechst Ag Prolonged action insulin analogues - with A1-glycine replaced by D-alanine or D-serine
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (en) * 1988-05-11 1988-05-11 Novo Industri As NEW PEPTIDES
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues

Also Published As

Publication number Publication date
AU8054391A (en) 1992-01-23
DK155690D0 (en) 1990-06-28
PT98124A (en) 1992-04-30
IL98596A0 (en) 1992-07-15
WO1992000321A1 (en) 1992-01-09
IE912247A1 (en) 1992-01-01
EP0536245A1 (en) 1993-04-14
NZ238718A (en) 1992-06-25
JPH05508406A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
ZA914830B (en) Novel,protracted insulin analogues
HU9200302D0 (en) 1,3-oxatiolane-nucleotide analogues
ZA893508B (en) Insulin analogues
DE58901334D1 (en) Difluorbenzolderivate.
DE58900568D1 (en) Duennschichtsolarzellenanordnung.
DE58904529D1 (en) Thermostatisiergeraet.
DE68900557D1 (en) Foerderer.
DE68907470D1 (en) Fluegelzellenpumpe.
DE68905877D1 (en) Tuerspiegelaufbau.
DE68907379D1 (en) Waeschetrockner.
DE58902248D1 (en) Buegeleisensohle.
DE69002642D1 (en) Flexible tampondruckmaschine.
DE68902332D1 (en) Oelabscheider.
DE58903464D1 (en) Chemosensitiver wandler.
DE58905558D1 (en) Whirlpool-düse.
DE68902898D1 (en) Ballhebemechanismus.
EP0605983A3 (en) Insulin analogs.
DE58904098D1 (en) N-aryltetrahydrophthalimidverbindungen.
DE58902743D1 (en) Substituierte n-aryl-stickstoffheterocyclen.
DE68907450D1 (en) Tuersteuerungsvorrichtung.
ZA898608B (en) 14alpha,17alpha-ethanoestratrienes
DE68900005D1 (en) Tank-container.
DE58904923D1 (en) Fluegelzellenverdichter.
DE58902926D1 (en) Isothiazolazofarbstoffe.
DE58902660D1 (en) Substituierte thiadiazolyloxyessigsaeureamide.